Clearing Muddy Waters: The Need to Reconceptualize Minor Increase over Minimal Risk in Pediatric Rare Disease Research

, &
American Journal of Bioethics 20 (4):8-10 (2020)
  Copy   BIBTEX

Abstract

Volume 20, Issue 4, May 2020, Page 8-10.

Categories

Keywords

Reprint years

DOI

10.1080/15265161.2020.1735868

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 91,829

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

My notes

Similar books and articles

Bringing Known Drugs to Pediatric Research: Safety, Efficacy, and the Ambiguous Minor Increase in Minimal Risk.Akshay Sharma & Liza-Marie Johnson - 2020 - American Journal of Bioethics 20 (4):106-108.
Defining the Boundaries of a Right to Adequate Protection: A New Lens on Pediatric Research Ethics.David DeGrazia, Michelle Groman & Lisa M. Lee - 2017 - Journal of Medicine and Philosophy 42 (2):132-153.
Greater Than Minimal Risk, No Direct Benefit – Bridging Drug Trials and Novel Therapy in Pediatric Populations.Benjamin S. Wilfond, Devan M. Duenas & Liza-Marie Johnson - 2020 - American Journal of Bioethics 20 (4):102-103.
Pediatric Magnetic Resonance Research and the Minimal-Risk Standard.Matthias Schmidt, Jennifer Marshall, Jocelyn Downie & Michael Hadskis - 2011 - IRB: Ethics & Human Research 33 (5):1-6.
Minimal risk revisited: the ethics of clinical research with children.Ariella Binik - unknown
Rethinking Risk in Pediatric Research.Kathleen Cranley Glass & Ariella Binik - 2008 - Journal of Law, Medicine and Ethics 36 (3):567-576.
Parents' Perspectives on the Consent Approach for Minimal-Risk Research Involving Children.Melissa Cameron, Lauren Marsillio, Linda Cushman & Marilyn Morris - 2011 - IRB: Ethics & Human Research 33 (6):6-13.
Improving the Helsinki Declaration's guidance on research in incompetent subjects.Anna Eva Westra & Inez de Beaufort - 2015 - Journal of Medical Ethics 41 (3):278-280.
Ethical Drug Development for Rare Childhood Diseases: When There Are Limited But Promising Data in Adults, How to Choose Between Safety or Efficacy Studies?Liza-Marie Johnson, Devan M. Duenas & Benjamin S. Wilfond - 2020 - American Journal of Bioethics 20 (4):111-113.
Flexibility Required: Balancing the Interests of Children and Risk in Drug Development for Rare Pediatric Conditions.Kathryn M. Porter, Anne Stevens & Benjamin S. Wilfond - 2020 - American Journal of Bioethics 20 (4):116-118.
Determining Risk in Pediatric Research with No Prospect of Direct Benefit: Time for a National Consensus on the Interpretation of Federal Regulations.Celia B. Fisher - 2007 - American Journal of Bioethics 7 (3):5-10.
Why Even Inappropriate Parental Consent Might Be Enough to Justify Minimal Risk Pediatric Research Without Clinical Benefit.David Hunter - 2012 - American Journal of Bioethics 12 (1):35 - 36.
Complex calculations: ethical issues in involving at-risk healthy individuals in dementia research.R. Pierce - 2010 - Journal of Medical Ethics 36 (9):553-557.
On the Minimal Risk Threshold in Research With Children.Ariella Binik - 2014 - American Journal of Bioethics 14 (9):3-12.
Why the Debate over Minimal Risk Needs to be Reconsidered.Ariella Binik & Charles Weijer - 2014 - Journal of Medicine and Philosophy 39 (4):387-405.

Analytics

Added to PP
2020-03-25

Downloads
12 (#1,082,941)

6 months
5 (#632,816)

Historical graph of downloads
How can I increase my downloads?

Author's Profile

Citations of this work

Add more citations

References found in this work

View all 9 references / Add more references